Treatment

DETERMINATION study potentially significant for myeloma treatment

June 21, 2022

1 min view

&#13
Supply/Disclosures&#13

&#13
Source: &#13
Healio Interview&#13

&#13
Disclosures: &#13
Richardson reviews consulting for and/or acquiring research assist from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, and Takeda.&#13


We have been not able to course of action your ask for. Make sure you test again later on. If you continue on to have this issue please get hold of [email protected]

In this video, Paul Richardson, MD, director of scientific research at Jerome Lipper Several Myeloma Heart at Dana-Farber Most cancers Institute, discusses the stage III Willpower analyze in numerous myeloma offered at ASCO Annual Assembly.

Richardson introduces the examine, which examined the use of lenalidomide, bortezomib and dexamethasone (RVd) in tandem with stem mobile transplantation and lenalidomide steady maintenance in clients freshly diagnosed with several myeloma below the age of 65, and gives context for its significance in the remedy of various myeloma.

“The final results, we imagine, are of specific value and, ideally, really handy in informing follow for a amount of reasons,” Richardson stated.

Reference:

  • Richardson P, et al. Offered at: ASCO Yearly Conference June 3-7, 2022 Chicago.

Related Articles

Leave a Reply

Back to top button